News

Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024

Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Tubulis to Present Preclinical Proof-of-Concept Data for Two Lead ADC Candidates Targeting Solid Tumors at the AACR Annual Meeting 2024

Tubulis publishes article in Molecular Cancer Therapeutics on advantages of its proprietary P5/Tubutecan platform

Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients

Article on Tubulis’ novel ADC conjugation technology P5 makes it to the cover of Chemical Science!

Tubulis Appoints Seasoned ADC Expert Björn Hock as Chief Development Officer

New Tubulis Paper in Blood highlights potential of next-generation ADC for effective & safe treatment of acute myeloid leukemia

ERP Article: Actualising the Power of Antibody-Drug Conjugates as Cancer Therapeutics

Tubulis moves into the Innovation and Startup Center for Biotechnology IZB in Martinsried

Tubulis Welcomes Mary Ann Lumiqued as Vice President Program Management

Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies

Olivier Marcq Joins Tubulis as Vice President CMC

Tubulis Publishes Deep-dive into Proprietary P5-Conjugation Technology in European Journal of Organic Chemistry

Tubulis Welcomes Magdalena Zikmundova as Associate Medical Director and Armin Weidmann as Vice President Quality

Tubulis Establishes Scientific Advisory Board with Leading ADC Drug Development and Oncology Experts

Tubulis Appoints Christian Grøndahl as Independent Chairman to Lead Supervisory Board

Tubulis appoints Günter Fingerle-Rowson as Chief Medical Officer to lead the clinical development of its new generation of ADCs

Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi STA to Advance New Generation of Antibody-Drug Conjugates towards Clinical Evaluation

Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates